Study:"Autoimmunity [not] adequate...to explain MS"
Posted: Sat Mar 19, 2005 4:19 pm
Interesting new study proposing a dual MS autoimmune/infection pathogenesis...
Fortschr Neurol Psychiatr. 2005 Marz;73(3):143-149. Related Articles, Links
[Differential Influence of Immune Therapy on Relapses and Progression in Multiple Sclerosis: Interpretation and Therapeutic Consequences.]
[Article in German]
Kornhuber ME, Presek P, Zierz S.
Klinik fur Neurologie der Martin-Luther-Universitat Halle-Wittenberg (Direktor Prof. Dr. S. Zierz). malte.kornhuber@medizin.uni-halle.de.
It is well established that relapses can be suppressed by different substances in patients with relapsing-remitting multiple sclerosis (MS). In contrast, patients with progressive forms of MS do hardly respond to immune therapy. Therefore, start of immune therapy after the first relapse has been proposed, especially in order to prevent degeneration and disability. This view is challenged in the present review. Actually no evidence exists in support of a retardation or an attenuation of secondary progression by early immune therapy. Widespread degeneration occurs early and progresses independently from inflammatory plaques. Therefore, autoimmunity per se is no adequate paradigm to explain MS-pathogenesis entirely. A virus/superantigen-dualism is proposed to explain the different parts of MS, instead. It is concluded that evidence-based immune therapy should be adapted to the actual inflammatory activity of the disease. A suitable parameter for this purpose is the interval between 2 relapses.
PMID: 15747223 [PubMed - as supplied by publisher]
Fortschr Neurol Psychiatr. 2005 Marz;73(3):143-149. Related Articles, Links
[Differential Influence of Immune Therapy on Relapses and Progression in Multiple Sclerosis: Interpretation and Therapeutic Consequences.]
[Article in German]
Kornhuber ME, Presek P, Zierz S.
Klinik fur Neurologie der Martin-Luther-Universitat Halle-Wittenberg (Direktor Prof. Dr. S. Zierz). malte.kornhuber@medizin.uni-halle.de.
It is well established that relapses can be suppressed by different substances in patients with relapsing-remitting multiple sclerosis (MS). In contrast, patients with progressive forms of MS do hardly respond to immune therapy. Therefore, start of immune therapy after the first relapse has been proposed, especially in order to prevent degeneration and disability. This view is challenged in the present review. Actually no evidence exists in support of a retardation or an attenuation of secondary progression by early immune therapy. Widespread degeneration occurs early and progresses independently from inflammatory plaques. Therefore, autoimmunity per se is no adequate paradigm to explain MS-pathogenesis entirely. A virus/superantigen-dualism is proposed to explain the different parts of MS, instead. It is concluded that evidence-based immune therapy should be adapted to the actual inflammatory activity of the disease. A suitable parameter for this purpose is the interval between 2 relapses.
PMID: 15747223 [PubMed - as supplied by publisher]